It has been shown that nasal continuous positive airway pressure (nasal CPAP) significantly reduces nocturnal reflux both in patients with sleep apnea and in patients without sleep apnea but consistent abnormal nocturnal reflux. The mechanism by which CPAP is thought to reduce reflux includes the elevation of the resting lower esophageal sphincter (LES) pressure. In this study, we tested the effect of nasal CPAP in two groups of patients with aperistaltic esophagus but with different resting LES pressure. Seven patients with scleroderma esophagus and six patients treated for achalasia were tested over a 48-h period. On the first night, the patients were untreated; on the second night, both groups received applied nasal CPAP at 8 cm H20 pressure. The percentage of time the pH <4.0, the number of reflux events >5 N asal continuous positive airway pressure (CPAP) has been shown to reduce nocturnal gastroesophageal reflux (GER) 
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Patients With Achalasia
Six patients with achalasia who had been treated by pneumatic dilatation (n=3) or transthoracic limited myotomy without fundoplication (n=3) were studied. These were consecutive patients selected by a previous abnormal nocturnal pH study. These patients ranged in age from 32 to 71 years (mean, 46 years). The follow-up time since treatment was 3.1 ± 1.1 months.
Polysomnography
Polysomnography was done to exclude sleep apnea and consisted of 8 The percentage of time the pH was less than 4.0 on night 1 ranged from 11.7 to 57.6 percent (38.5 ± 20.6 percent); on night 2, 0.0 to 14.3 percent (2.9±5.6 percent) (p=0.014). The number of reflux episodes 100 on night 1 ranged from 1 to 17 (6.5 ± 6.5); on CPAP, the range was 0 to 5 (1.8 ± 1.9) (p=0.05). The number of reflux episodes longer than 5 The individual responses to CPAP for both groups of patients are found in Figure 1 . Typical patient 24-h pH monitoring for a patient with achalasia with CPAP intervention in the second night is found in Figure 2 ; for a patient with scleroderma, Figure 3 21:00 01:00 min to 13.8±6.9 min (p<O.O1) of reflux events.2 This reduction of reflux was demonstrated without altering the patient's arousal frequency. No change was seen in the amount of daytime reflux, day 1 to day 2. In the same study, the mechanism of this phenomenon was investigated in six volunteers with normal esophageal function. A routine esophageal motility examination was conducted and 8 cm H20 pressure of nasal CPAP was then applied during the course of another complete esophageal motility test. Resting LES pressure and the intraesophageal resting pressure were both found to be significantly (p<0.05) increased following the application of CPAP. Wave velocity, amplitude, and duration were unchanged.
In the present study, 8 cm H20 CPAP was found to reduce nocturnal reflux in treated patients with achalasia. No consistent effect was found in patients with scleroderma esophagus. It is unknown whether using a higher pressure may have been effective in the patients with scleroderma. This may indicate that an important factor involved in the reduction of nocturnal reflux was the residual resting pressure of the LES in the patients with achalasia. The mean resting LES pressure in the patient groups in two other studies in which CPAP was successful in reducing nocturnal reflux was 14.1 and 14.6 mm Hg; this was comparable to the resting LES pressure in the group of patients with achalasia described herein (17.1 ± 5.8 mg), and significantly greater (p<0.01) than was found in the patients with scleroderma (2.4 ± 1.3 mm Hg).
Both of these patient groups are known to develop complications secondary to reflux. three of the patients with achalasia from this study are using home nasal CPAP.
In conclusion, we believe that nasal CPAP reduces nocturnal reflux in patients who have residual LES pressure in excess of that found in patients with scleroderma esophagus (those >10 mm Hg). In studies of patients with resting LES pressure of 14.1, 14.6, and 17.1 mm fig, nasal CPAP was found to reduce nocturnal reflux significantly. It is not known at present whether long-term CPAP use will prevent reflux-associated complications in patients with achalasia who demonstrate nocturnal reflux. However, further study of nasal CPAP on nocturnal reflux appears warranted.
